NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority Mar 19 2009

NEW YORK, March 19 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an agreement with Dr. Vincent C. Giampapa, M.D., F.A.C.S. to open a new stem cell collection center at the Giampapa Institute for Anti-Aging Medical Therapy in Montclair, New Jersey. The agreement adds to NeoStem's national network of metropolitan stem cell collection centers, the most recent of which was in New York City. In February 2009, NeoStem announced it has licensed the exclusive worldwide rights to Dr. Giampapa's innovative stem cell technology and applications for cosmetic facial and body procedures and skin rejuvenation. Dr. Giampapa is a Board-certified plastic reconstructive surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at the University of Medicine and Dentistry of New Jersey. One of the first certified anti-aging medical physicians in the world, he is Director of the Plastic Surgery Center Internationale as well as The Giampapa Institute.

Dr. Giampapa is renowned for a non-surgical complete facial rejuvenation procedure that involves the use of adult stem cells. The procedure can be accomplished under local anesthesia in an office setting and requires only about a week of recovery time. He is also a founder of Suracell Inc. (www.suracell.com), which formulates for clients a personal genetic health program based on analysis of an individual's genetic profile. "We are currently performing Stem Cell Face Lifts and are looking forward to giving our patients the opportunity to have their stem cells collected today for multiple treatments in the future," said Dr. Giampapa.

NeoStem's collection centers utilize a minimally invasive proprietary system to enable health conscious consumers to donate and store their own stem cells when they are young and healthy, for personal use years or decades later in times of medical need. The Company's stem cell collection center model generates revenue for the Company through ongoing fees derived from stem cell collections and processing and fees charged to the centers for marketing and support. Long-term storage generates further revenue on a recurring basis.

Robin Smith, MD, CEO of NeoStem, said, "We are extremely pleased to have Dr. Giampapa's Institute join our network of collection centers. He is at the forefront of developing innovative stem cell therapies addressing anti-aging and regenerative medicine, an important arena for NeoStem. His prestige internationally as well as in the U.S. will draw clients from around the world, especially China, through NeoStem's relationships there. We look forward to a fruitful partnership with him on many fronts."